MDCX vs BMY
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Sep 11, 2026
MDCX
46.1
AI Score
VS
MDCX Wins
BMY
30.9
AI Score
Investment Advisor Scores
BMY
31score
Recommendation
SELL
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | MDCX | BMY | Winner |
|---|---|---|---|
| Net Income | -20.66M | 7.05B | BMY |
| ROE | 1171.4% | 38.2% | MDCX |
| ROA | -76.2% | 7.8% | BMY |
| Total Assets | 27.12M | 90.04B | BMY |
| Cash | 15.17M | 10.21B | BMY |
| Current Ratio | 1.57 | 1.26 | MDCX |
Relative Price Performance (Last 90 Days)
MDCX 1M: -55.2%
· 3M: -53.1%
BMY 1M: -0.8%
· 3M: +12.3%
Current Technical Phase
MDCX
MarkdownSell / avoid
Price below a falling SMA50 (slope -17.7%), weak momentum, RSI 26
BMY
NeutralHold
Mixed signals - no dominant trend phase, RSI 45
Fundamentals Snapshot
| Metric | MDCX | BMY |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -0.6 | 9.7 |
| Trailing P/E | — | 14.0 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.1% |
| Gross Margin | — | 0.7% |
| Operating Margin | 0.0% | 0.3% |
| EPS | -2.36 | 4.54 |
| Dividend Yield | — | 0.04% |
Frequently Asked Questions
Based on our detailed analysis, MDCX is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.